Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▲ +0.5% | ▲ +1.6% | ▲ +42.9% | ▲ +90.2% | ▲ +81.0% | ▲ +127.3% | ▼ −26.8% | ▲ +196.1% |
| Peer average | ▲ +1.2% | ▲ +4.5% | ▲ +9.5% | ▲ +22.6% | ▲ +30.8% | ▲ +76.1% | ▲ +30.8% | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2021-12-29 | 2021-12-31 | $0.38 |
| 2020-12-29 | 2020-12-31 | $0.79 |
| 2019-12-27 | 2019-12-31 | $1.05 |
| 2018-12-27 | 2018-12-31 | $0.47 |
| 2017-12-27 | 2017-12-29 | $0.33 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind ARKG.